ABSTRACT
RAMIPRIL Trade names: Altace (Monarch), Tritace (SanofiAventis) Indications: Hypertension Class: Angiotensin-converting enzyme (ACE) inhibitor, Antihypertensive, Vasodilator Half-life: 2-17 hours Clinically important, potentially hazardous interactions with: alcohol, aldesleukin, allopurinol, alpha blockers, alprostadil, amifostine, amiloride, angiotensin II receptor antagonists, antacids, antihypertensives, antipsychotics, azathioprine, baclofen, beta blockers, calcium channel blockers, clonidine, corticosteroids, cyclosporine, diazoxide, diuretics, eplerenone, estrogens, everolimus, general anesthetics, gold & gold compounds, heparins, hydralazine, hypotensives, insulin, levodopa, lithium, MAO inhibitors, metformin, methyldopa, minoxidil, moxisylyte, moxonidine, nitrates, nitroprusside, NSAIDs, pentoxifylline, phosphodiasterase 5 inhibitors, potassium salts, prostacyclin analogues, quinine, rituximab, sirolimus, spironolactone, sulfonylureas, telmisartan, temsirolimus, tizanidine, tolvaptan, triamterene, trimethoprim Pregnancy category: D (category C in first trimester; category D in second and third trimesters) Note: Contraindicated in patients with a history of angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema.
